These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 15692974)

  • 1. Rituximab in the treatment of dermatomyositis: an open-label pilot study.
    Levine TD
    Arthritis Rheum; 2005 Feb; 52(2):601-7. PubMed ID: 15692974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot trial of rituximab in the treatment of patients with dermatomyositis.
    Chung L; Genovese MC; Fiorentino DF
    Arch Dermatol; 2007 Jun; 143(6):763-7. PubMed ID: 17576943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients.
    Cooper MA; Willingham DL; Brown DE; French AR; Shih FF; White AJ
    Arthritis Rheum; 2007 Sep; 56(9):3107-11. PubMed ID: 17763414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.
    Albert D; Dunham J; Khan S; Stansberry J; Kolasinski S; Tsai D; Pullman-Mooar S; Barnack F; Striebich C; Looney RJ; Prak ET; Kimberly R; Zhang Y; Eisenberg R
    Ann Rheum Dis; 2008 Dec; 67(12):1724-31. PubMed ID: 18250115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab as therapy for refractory polymyositis and dermatomyositis.
    Noss EH; Hausner-Sypek DL; Weinblatt ME
    J Rheumatol; 2006 May; 33(5):1021-6. PubMed ID: 16541475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
    Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
    Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
    Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
    Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.
    Tokunaga M; Fujii K; Saito K; Nakayamada S; Tsujimura S; Nawata M; Tanaka Y
    Rheumatology (Oxford); 2005 Feb; 44(2):176-82. PubMed ID: 15494350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.
    Looney RJ; Anolik JH; Campbell D; Felgar RE; Young F; Arend LJ; Sloand JA; Rosenblatt J; Sanz I
    Arthritis Rheum; 2004 Aug; 50(8):2580-9. PubMed ID: 15334472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
    Kerl K; Prins C; Saurat JH; French LE
    Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.
    Leandro MJ; Cambridge G; Edwards JC; Ehrenstein MR; Isenberg DA
    Rheumatology (Oxford); 2005 Dec; 44(12):1542-5. PubMed ID: 16188950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.
    Sfikakis PP; Boletis JN; Lionaki S; Vigklis V; Fragiadaki KG; Iniotaki A; Moutsopoulos HM
    Arthritis Rheum; 2005 Feb; 52(2):501-13. PubMed ID: 15693003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus.
    Marks SD; Patey S; Brogan PA; Hasson N; Pilkington C; Woo P; Tullus K
    Arthritis Rheum; 2005 Oct; 52(10):3168-74. PubMed ID: 16200620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment.
    Roll P; Dörner T; Tony HP
    Arthritis Rheum; 2008 Jun; 58(6):1566-75. PubMed ID: 18512772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease.
    Younes A; Romaguera J; Hagemeister F; McLaughlin P; Rodriguez MA; Fiumara P; Goy A; Jeha S; Manning JT; Jones D; Abruzzo LV; Medeiros LJ
    Cancer; 2003 Jul; 98(2):310-4. PubMed ID: 12872350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
    Higashida J; Wun T; Schmidt S; Naguwa SM; Tuscano JM
    J Rheumatol; 2005 Nov; 32(11):2109-15. PubMed ID: 16265687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.
    Dastmalchi M; Grundtman C; Alexanderson H; Mavragani CP; Einarsdottir H; Helmers SB; Elvin K; Crow MK; Nennesmo I; Lundberg IE
    Ann Rheum Dis; 2008 Dec; 67(12):1670-7. PubMed ID: 18272672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.